Lab monitoring guidelines US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Lab monitoring guidelines. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Lab monitoring guidelines US Medical PG Question 1: A 17-year-old male presents to your office complaining of polyuria, polydipsia, and unintentional weight loss of 12 pounds over the past 3 months. On physical examination, the patient is tachypneic with labored breathing. Which of the following electrolyte abnormalities would you most likely observe in this patient?
- A. Hypophosphatemia
- B. Hypermagnesemia
- C. Hyperkalemia
- D. Hyponatremia (Correct Answer)
- E. Hyperphosphatemia
Lab monitoring guidelines Explanation: ***Hyponatremia***
- This patient's symptoms of polyuria, polydipsia, and weight loss, along with **tachypnea and labored breathing**, are highly suggestive of **diabetic ketoacidosis (DKA)**.
- **Hyponatremia** is the **most consistently observed** electrolyte abnormality in DKA, present in nearly all cases at initial presentation.
- This is typically **pseudohyponatremia** caused by the osmotic effect of severe hyperglycemia—glucose pulls water into the extracellular space, diluting the measured sodium concentration.
- The **corrected sodium** can be calculated using: Corrected Na = Measured Na + 0.016 × (Glucose - 100), which typically reveals a more normal sodium level.
- True hyponatremia from sodium loss via **osmotic diuresis** can also occur but is usually masked by the dilutional effect.
*Hyperkalemia*
- While serum potassium may appear normal or even elevated initially due to **transcellular shifts** (acidosis causes potassium to move from intracellular to extracellular space in exchange for hydrogen ions), this is not the most consistently observed abnormality.
- **Total body potassium is always depleted** in DKA due to osmotic diuresis and vomiting.
- Many patients present with normal or even low potassium levels despite acidosis.
- Potassium levels require careful monitoring during treatment as insulin therapy drives potassium back into cells, potentially causing life-threatening hypokalemia.
*Hypophosphatemia*
- While **phosphate levels** can fluctuate in DKA due to osmotic diuresis, initial presentation often involves normal or even elevated phosphate levels due to cellular shifts.
- Significant **hypophosphatemia** is more typically observed during treatment as insulin drives phosphate back into the cells, similar to potassium.
*Hypermagnesemia*
- **Hypermagnesemia** is uncommon in DKA and is usually associated with impaired renal excretion or excessive magnesium intake.
- The symptoms described do not point towards magnesium imbalance.
*Hyperphosphatemia*
- Although cellular shifts can initially raise serum phosphate, sustained **hyperphosphatemia** is not a characteristic or common electrolyte abnormality seen in the acute presentation of DKA.
- More typically, total body phosphate is depleted due to **osmotic diuresis**.
Lab monitoring guidelines US Medical PG Question 2: A 32-year-old woman comes to the office for a regular follow-up. She was diagnosed with type 2 diabetes mellitus 4 years ago. Her last blood test showed a fasting blood glucose level of 6.6 mmol/L (118.9 mg/dL) and HbA1c of 5.1%. No other significant past medical history. Current medications are metformin and a daily multivitamin. No significant family history. The physician wants to take her blood pressure measurements, but the patient states that she measures it every day in the morning and in the evening and even shows him a blood pressure diary with all the measurements being within normal limits. Which of the following statements is correct?
- A. The physician has to measure the patient’s blood pressure because it is a standard of care for any person with diabetes mellitus who presents for a check-up. (Correct Answer)
- B. Assessment of blood pressure only needs to be done at the initial visit; it is not necessary to measure blood pressure in this patient at any follow-up appointments.
- C. The physician should not measure the blood pressure in this patient and should simply make a note in a record showing the results from the patient’s diary.
- D. The physician should not measure the blood pressure in this patient because she does not have hypertension or risk factors for hypertension.
- E. The physician should not measure the blood pressure in this patient because the local standards of care in the physician's office differ from the national standards of care so measurements of this patient's blood pressure cannot be compared to diabetes care guidelines.
Lab monitoring guidelines Explanation: **The physician has to measure the patient’s blood pressure because it is a standard of care for any person with diabetes mellitus who presents for a check-up.**
- For individuals with **diabetes mellitus**, regular **blood pressure monitoring** by a healthcare professional is a fundamental component of their routine care, regardless of home measurements.
- This practice ensures accuracy, identifies **white coat hypertension**, and allows for early detection and management of **cardiovascular risks** inherent to diabetes.
*Assessment of blood pressure only needs to be done at the initial visit; it is not necessary to measure blood pressure in this patient at any follow-up appointments.*
- This statement is incorrect as **regular blood pressure monitoring** is essential for all follow-up visits in diabetic patients due to their elevated risk of developing **hypertension** and associated complications.
- Even if initial measurements are normal, blood pressure can change over time, necessitating continuous assessment to maintain optimal **cardiovascular health**.
*The physician should not measure the blood pressure in this patient and should simply make a note in a record showing the results from the patient’s diary.*
- Relying solely on **patient-recorded blood pressure** measurements, while valuable, does not replace the need for an **in-office measurement** by a healthcare provider.
- This is crucial for verifying the accuracy of home devices, assessing for **masked hypertension**, and ensuring compliance with **clinical guidelines**.
*The physician should not measure the blood pressure in this patient because she does not have hypertension or risk factors for hypertension.*
- This is incorrect; the patient's diagnosis of **Type 2 Diabetes Mellitus** itself is a significant **risk factor for hypertension** and cardiovascular disease.
- All individuals with diabetes require ongoing **blood pressure monitoring**, irrespective of their current blood pressure status or other obvious risk factors.
*The physician should not measure the blood pressure in this patient because the local standards of care in the physician's office differ from the national standards of care so measurements of this patient's blood pressure cannot be compared to diabetes care guidelines.*
- This statement is generally incorrect and illogical; **national guidelines** for diabetes care, including blood pressure monitoring, are established to ensure consistent and high-quality care across different settings.
- Healthcare providers are expected to adhere to these **national standards of care** or explain any deviations, making the measurement of blood pressure a critical part of a diabetic patient's visit.
Lab monitoring guidelines US Medical PG Question 3: A 68-year-old man undergoes successful mechanical prosthetic aortic valve replacement for severe aortic valve stenosis. After the procedure, he is started on an oral medication and instructed that he should take for the rest of his life and that he should avoid consuming large amounts of dark-green, leafy vegetables. Which of the following laboratory parameters should be regularly monitored to guide dosing of this drug?
- A. D-dimer
- B. Anti-factor Xa activity
- C. Activated partial thromboplastin time
- D. Prothrombin time (Correct Answer)
- E. Thrombin time
Lab monitoring guidelines Explanation: ***Prothrombin time***
- **Warfarin** is the standard chronic anticoagulant post-mechanical valve replacement, and its dosing is monitored using the **prothrombin time (PT)**, reported as the **International Normalized Ratio (INR)**.
- The avoidance of dark-green, leafy vegetables indicates a **Vitamin K antagonist**, which is warfarin.
*D-dimer*
- **D-dimer** levels are primarily used to rule out **venous thromboembolism (VTE)** and are not used for routine monitoring of chronic anticoagulation.
- Elevated D-dimer indicates recent or ongoing **fibrinolysis**, which is not directly targeted by warfarin therapy.
*Anti-factor Xa activity*
- **Anti-factor Xa activity** is used to monitor the anticoagulant effect of **low molecular weight heparins (LMWH)** or **direct oral anticoagulants (DOACs)** like rivaroxaban or apixaban.
- This patient is on a vitamin K antagonist, not an anti-Xa inhibitor.
*Activated partial thromboplastin time*
- The **activated partial thromboplastin time (aPTT)** is used to monitor patients receiving **unfractionated heparin**, not warfarin.
- While both heparin and warfarin are anticoagulants, they act on different parts of the coagulation cascade and are monitored differently.
*Thrombin time*
- **Thrombin time (TT)** measures the time it takes for plasma to clot after adding thrombin, and it is primarily used to detect inherited or acquired **fibrinogen disorders** or to monitor **direct thrombin inhibitors**.
- It is not routinely used for monitoring warfarin therapy.
Lab monitoring guidelines US Medical PG Question 4: A research team is studying the effects of a novel drug that was discovered to treat type 2 diabetes. In order to learn more about its effects, they follow patients who are currently taking the drug and determine whether there are adverse effects that exceed anticipated levels and may therefore be drug-related. They discover that the drug causes an excess of sudden cardiac death in 19 patients with renal failure out of 2 million total patients that are followed. Based on these results, an additional warning about this serious adverse effect is added to the investigator brochure for the drug. Which of the following clinical phase studies does this study most likely describe?
- A. Phase IV (Correct Answer)
- B. Phase II
- C. Phase V
- D. Phase III
- E. Phase I
Lab monitoring guidelines Explanation: ***Phase IV***
- This study occurs **after a drug has been approved and marketed**, focusing on post-marketing surveillance for long-term safety, effectiveness, and real-world side effects in a large and diverse patient population.
- The discovery of a rare but serious adverse effect (sudden cardiac death) in a large patient population (2 million) after the drug is already in use is characteristic of a **Phase IV clinical trial**.
*Phase II*
- Phase II trials involve a **larger group of patients (hundreds)** and focus on evaluating the drug's effectiveness and further assessing safety in patients with the target condition.
- This phase is typically conducted **before widespread marketing** and would not involve 2 million patients.
*Phase V*
- There is **no widely recognized "Phase V"** in standard clinical trial terminology (Phases I-IV focus on drug development and post-marketing surveillance).
- This term is sometimes used informally to refer to **health economics and outcomes research** or implementation studies, which are not described in the scenario.
*Phase III*
- Phase III trials are large-scale studies involving **thousands of patients** to confirm effectiveness, monitor side effects, compare the drug to standard treatments, and collect information for safe use.
- While large, these trials are conducted **before regulatory approval** and marketing, and would not typically follow 2 million patients already taking the drug in the real world.
*Phase I*
- Phase I trials are the **first stage of human testing**, involving a small group of healthy volunteers (20-100) to assess safety, dosage, and pharmacokinetics.
- The primary goal is to determine if the drug is safe enough for further testing, not to identify rare adverse events in a large patient population.
Lab monitoring guidelines US Medical PG Question 5: A 50-year-old woman comes to the physician for a routine health maintenance examination. She has no personal or family history of serious illness. She smoked one pack of cigarettes daily for 5 years during her 20s. Her pulse is 70/min, and blood pressure is 120/78 mm Hg. Serum lipid studies and glucose concentration are within the reference ranges. Which of the following health maintenance recommendations is most appropriate at this time?
- A. Perform BRCA gene test
- B. Perform abdominal ultrasound
- C. Perform 24-hour ECG
- D. Perform DEXA scan
- E. Perform colonoscopy (Correct Answer)
Lab monitoring guidelines Explanation: ***Perform colonoscopy***
- **Colorectal cancer screening** with colonoscopy is generally recommended for individuals at average risk starting at age **45-50 years**.
- This patient is **50 years old** and has no increased risk factors, making routine colonoscopy the most appropriate screening.
*Perform BRCA gene test*
- **BRCA gene testing** is indicated for individuals with a strong **family history** of breast or ovarian cancer, or those with personal history suggesting a genetic predisposition.
- This patient has **no personal or family history** of serious illness, so BRCA testing is not warranted.
*Perform abdominal ultrasound*
- **Abdominal ultrasound** is typically used to investigate specific symptoms or screen for conditions like **abdominal aortic aneurysm** in high-risk individuals (e.g., male smokers over 65).
- This patient has **no relevant symptoms** or risk factors for which routine abdominal ultrasound screening is recommended.
*Perform 24-hour ECG*
- A **24-hour ECG (Holter monitor)** is used to detect paroxysmal **arrhythmias** or evaluate symptoms like palpitations, syncope, or dizziness.
- This patient is asymptomatic with a normal pulse and blood pressure; therefore, **routine 24-hour ECG** is not indicated.
*Perform DEXA scan*
- A **DEXA scan** is recommended for **osteoporosis screening** in women typically starting at age **65**, or earlier if they have significant risk factors like a history of fragility fractures or certain medical conditions.
- At **50 years old** and with no apparent risk factors for osteoporosis, a DEXA scan is not yet routinely indicated according to general guidelines.
Lab monitoring guidelines US Medical PG Question 6: A 21-year-old woman is admitted to the hospital for severe malnutrition with a BMI of 15 kg/m2. Past medical history is significant for chronic anorexia nervosa. During the course of her stay, she is treated with parenteral fluids and nutrition management. On the 4th day, her status changes. Her blood pressure is 110/75 mm Hg, heart rate is 120/min, respiratory rate is 25/min, and temperature is 37.0°C (98.6°F). On physical exam, her heart is tachycardic with a regular rhythm and her lungs are clear to auscultation bilaterally. She appears confused, disoriented, and agitated. Strength in her lower extremities is 4/5. What is the next step in management?
- A. MRI of the brain
- B. Administer insulin
- C. Measure electrolytes (Correct Answer)
- D. Arrange for outpatient counseling
- E. Doppler ultrasound on lower extremities
Lab monitoring guidelines Explanation: ***Measure electrolytes***
- The patient's presentation with **confusion, disorientation, agitation**, and **lower extremity weakness** after refeeding for severe **malnutrition** is highly suggestive of **refeeding syndrome**. This syndrome is characterized by severe electrolyte shifts, particularly **hypophosphatemia**, **hypokalemia**, and **hypomagnesemia**.
- Measuring electrolytes immediately is crucial to diagnose and then correct these imbalances, which can lead to life-threatening complications like **cardiac arrhythmias**, **respiratory failure**, and **seizures**.
*MRI of the brain*
- While neurological symptoms are present, a brain MRI is not the immediate first step given the context of refeeding in a severely malnourished patient.
- The symptoms are more consistent with **metabolic derangements** associated with **refeeding syndrome** than an acute primary neurological event.
*Administer insulin*
- Administering insulin without knowing the patient's glucose or electrolyte status could be dangerous, especially given the increased risk of **hypokalemia** and **hypophosphatemia** in refeeding syndrome, which insulin can exacerbate.
- Refeeding syndrome typically involves glucose shifts, but **hypoglycemia** is not the primary immediate concern, and hyperinsulinemia in this context can cause cellular uptake of electrolytes leading to further depletion.
*Arrange for outpatient counseling*
- The patient is acutely ill and experiencing a potentially life-threatening complication requiring immediate medical intervention.
- **Outpatient counseling** is not appropriate for an acute hospital admission with severe, rapidly changing symptoms.
*Doppler ultrasound on lower extremities*
- While immobility can increase the risk of deep vein thrombosis (DVT), the patient's symptoms of **confusion, agitation, tachycardia, tachypnea**, and **weakness** are not primary indicators of DVT.
- The clinical picture points strongly towards **metabolic complications** of refeeding.
Lab monitoring guidelines US Medical PG Question 7: A 55-year-old male presents to his primary care physician for a normal check-up. He has a history of atrial fibrillation for which he takes metoprolol and warfarin. During his last check-up, his international normalized ratio (INR) was 2.5. He reports that he recently traveled to Mexico for a business trip where he developed a painful red rash on his leg. He was subsequently prescribed an unknown medication by a local physician. The rash resolved after a few days and he currently feels well. His temperature is 98.6°F (37°C), blood pressure is 130/80 mmHg, pulse is 95/min, and respirations are 18/min. Laboratory analysis reveals that his current INR is 4.5. Which of the following is the most likely medication this patient took while in Mexico?
- A. Griseofulvin
- B. Rifampin
- C. St. John’s wort
- D. Trimethoprim-sulfamethoxazole (Correct Answer)
- E. Phenobarbital
Lab monitoring guidelines Explanation: ***Trimethoprim-sulfamethoxazole***
- **Trimethoprim-sulfamethoxazole** is a potent inhibitor of **CYP2C9**, the primary enzyme responsible for metabolizing **warfarin**, leading to significantly increased INR and bleeding risk.
- The patient's **elevated INR (4.5)** from a previous stable level of 2.5 strongly suggests an interaction with a medication that inhibits warfarin metabolism, and trimethoprim-sulfamethoxazole is a common culprit.
- TMP-SMX is commonly used to treat **cellulitis** and other skin infections, which aligns with the clinical presentation of a painful red rash.
*Griseofulvin*
- **Griseofulvin** is an antifungal agent that acts as a **CYP inducer**, which would *increase* warfarin metabolism and lead to a *decreased* INR, not the elevated INR seen in this patient.
- While it could treat fungal skin infections (e.g., tinea), it would cause the opposite effect on warfarin levels.
*Rifampin*
- **Rifampin** is a strong **CYP inducer**, meaning it would *increase* warfarin metabolism and thus *decrease* INR, leading to a higher risk of clotting, which is the opposite of what is seen in this patient.
- It is often used for tuberculosis or serious bacterial infections, not typically for a simple skin rash.
*St. John's wort*
- **St. John's wort** is a known **CYP inducer**, similar to rifampin, and would lead to a *decrease* in warfarin levels and INR.
- It is an herbal supplement primarily used for depression and would not typically be prescribed by a physician for a rash.
*Phenobarbital*
- **Phenobarbital** is a potent **CYP inducer**, which would *accelerate* warfarin metabolism and result in a *decreased* INR, increasing the risk of thrombosis.
- It is an anticonvulsant and sedative, not a medication typically prescribed for a rash.
More Lab monitoring guidelines US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
